Eton Pharmaceuticals, Inc. (ETON)
NasdaqGM · USD · Healthcare · Drug Manufacturers - Specialty & Generic
$50.17 (+0.34%) as of
Key statistics
- Market cap
- 1.43B
- P/E (TTM)
- 125.42
- Forward P/E
- 19.67
- EPS (TTM)
- 0.40
- Dividend yield
- 0.00%
- 52-week range
- 14.27 – 66.37
- Beta
- 0.90
- Revenue (TTM)
- 105.59M
- Profit margin
- 12.02%
- Analyst target
- $71.50
- Volume
- 399.11k
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Deer Park, IL, United States
- Employees
- 44
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.